New standardized purity tests would prevent unscrupulous CBD companies gaming the system to secure favorable results, says a U.K. industry body. The London-based Centre for Medicinal Cannabis (CMC) is to gauge the appetitive for a new set of internationally-recognized CBD testing guidelines. In a press release the CMC says […]

German medical cannabis company Demecan has secured 7 million euros ($7.6 million) in financing to expand production in Europe’s largest medical market. The fresh capital – from btov Partners, a European venture capital firm, and a German single family office – comes as international companies establish footholds in the important European Union market. Constantin von […]

The first European deal for Canadian firm MediPharm Labs will see its medical cannabis products made available to 20,000 German pharmacies. With dual listings on the Ontario and Frankfurt stock exchanges, MediPharm says this new deal is an important milestone in its global ambitions. And, it follows hot on […]

One of the leading lights of the European cannabis scene has successfully completed its demerger – as speculation mounts that a stock market flotation is imminent. London and Dublin-based European Cannabis Holdings (ECH) has split into distinct media and medical cannabis divisions, each with a trio of well-known brands. […]

This year ENCOD’s General Assembly was held in Austria, Carinthia, Liebenfels, from 13th-15th September 2019. 23 ENCOD members from 10 European countries attended the assembly and elected 1 new member to complete the EC, as one member from last year’s GA dropped out. We proudly announce that our Executive […]

Patients in over 30 European countries could soon be able to get access to GW Pharmaceuticals Epidyolex cannabis medicine after it was approved by the European Commission. Since its launch in the U.S last year GW’s sales have rocketed with Epidiolex (as it is known in America) boosting its […]

The European Commission granted marketing authorization to Epidyolex, the trade name in Europe for Epidiolex, GW Pharmaceuticals announced Monday. In June 2018, the U.S. Food and Drug Administration approved Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older. The CBD-based […]



October 2019
« Sep